keyword
MENU ▼
Read by QxMD icon Read
search

The Lancet Oncology

keyword
https://www.readbyqxmd.com/read/27924743/drug-approval-by-regulators-who-watches-the-watchers
#1
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27871732/crisis-point-for-radiology-and-oncology-workforces
#2
EDITORIAL
The Lancet
No abstract text is available yet for this article.
November 19, 2016: Lancet
https://www.readbyqxmd.com/read/27846913/induction-chemotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma
#3
Wen-Fei Li, Lei Chen, Ying Sun, Jun Ma
The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial" published in the Lancet Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5-fluorouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3-4N1/TxN2-3M0 NPC (ClinicalTrials...
November 15, 2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27842898/president-trump-into-the-unknown%C3%A2
#4
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
November 11, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27819226/cancer-drug-safety-time-to-re-focus-on-tackling-adverse-effects
#5
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27733256/making-paediatric-precision-oncology-a-reality
#6
The Lancet Oncology
No abstract text is available yet for this article.
October 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27599132/measuring-the-quality-of-cancer-care-in-uk-hospitals
#7
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
September 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27585992/assessing-second-look-tumour-resectability-in-childhood-posterior-fossa-ependymoma-a-centralised-review-panel-and-staging-tool-for-future-studies
#8
Christopher P Millward, Conor Mallucci, Tim Jaspan, Donald Macarthur, Richard Heyward, Tim Cox, Kung Chong, Richard G Grundy
PURPOSE: To improve uniformity in radiological review/reporting and discussion of surgical resection status in the forthcoming SIOP Ependymoma II trial, a central review of imaging and resection status will be carried out prior to treatment stratification. We present a review of surgical decision-making from the UKCCSG/SIOP Ependymoma trial for very young children (<3 years) (Lancet Oncol 8:696-705, 2007) and propose a primary surgical staging system for residual disease that could be used for Ependymoma II...
September 1, 2016: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://www.readbyqxmd.com/read/27511144/shooting-for-the-moon-and-the-stars
#9
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
August 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27396632/pancreatic-cancer-cause-for-optimism
#10
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
July 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27301024/impact-of-brexit-on-cancer-care-and-research
#11
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
May 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27301023/improved-drug-access-in-low-and-middle-income-countries
#12
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
May 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27300654/us-legislation-for-direct-to-consumer-advertising-paternalism-or-common-sense
#13
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
April 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27299260/when-is-a-carcinogen-not-a-carcinogen
#14
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27178681/asco-plenary-sessions-impact-legacy-future
#15
REVIEW
Andrae Vandross, Vinay Prasad, Sham Mailankody
The ASCO annual meeting draws a large crowd of physicians, cancer researchers, policy makers, and industry representatives. The crown jewel of the annual events is the Plenary session where impactful, influential and visible abstracts are selected for the largest audience. Plenary topics are frequently paired with concurrent New England Journal or Lancet publications.  Here, we review 9 years of ASCO plenary sessions.  Several themes emerge.  First, many of the topics selected have indeed been practice changing, such as the use of ALK inhibitors for ALK rearranged NSCLC, or checkpoint inhibitors in metastatic melanoma...
June 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/26972850/perceptions-of-cancer-in-society-must-change
#16
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
March 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26889491/the-best-timing-for-administering-systemic-chemotherapy-in-patients-with-locally-advanced-rectal-cancer
#17
Yusuke Shimodaira, Kazuto Harada, Quan Lin, Jaffer A Ajani
Over the past several decades, outcomes for patients with rectal cancer have improved considerably. However, several questions have emerged as survival times have lengthened and quality of life has improved for these patients. Currently patients with locally advanced rectal cancer (LARC) are often recommended multimodality therapy with fluoropyrimidine-based chemotherapy (CT) and radiation followed by total mesorectal excision (TME), with consideration given to FOLFOX before chemoradiotherapy (CRT). Recently, Garcia-Aguilar and colleagues reported in Lancet Oncology that the addition of mFOLFOX6 administered between CRT and surgery affected the number of patients achieving pathologic complete response (pathCR), which is of great interest from the standpoint of pursuit of optimal timing of systemic CT delivery...
January 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/26868335/liquid-cancer-biopsy-the-future-of-cancer-detection
#18
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
February 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26678187/15-years-of-the-lancet-oncology
#19
Lee S Schwartzberg
No abstract text is available yet for this article.
December 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26678185/the-lancet-oncology-15-years-and-counting%C3%A2
#20
David Collingridge
No abstract text is available yet for this article.
December 2015: Lancet Oncology
keyword
keyword
86611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"